12 Best AI Drug Discovery Stocks Hedge Funds Are Loading Up On

9. Absci Corporation (NASDAQ:ABSI)

Number of Hedge Fund Holders: 23

On June 15, Guggenheim raised its price target on Absci Corporation (NASDAQ:ABSI) to $15 from $10. The analyst maintained a “Buy” rating on the stock after a deeper review of ABS-201 ahead of interim proof of concept data expected in the second half of 2026.

Separately, Absci Corporation (NASDAQ:ABSI)’s ABS-201 carries more than $5 billion unadjusted US sales potential. It is expanding to over $8 billion, including former US markets.

Absci Corporation (NASDAQ:ABSI) CEO Sean McClain, speaking on recent developments, said: “2026 is going to be a data-rich year.” He commented that ABS-201, which is an AI-designed anti-prolactin receptor antibody for androgenetic alopecia, could represent a new mechanism of action in nearly three decades, with a dosing interval of only a few injections per year.

McClain also announced ABS-202, a second anti-PRLR antibody in preclinical development for an undisclosed inflammation and immunology indication as part of an expanded pipeline built on prolactin biology.

The corporation reported completion of four SAD cohorts in its Phase 1/2a HEADLINE trial. It stated ABS-201 remains well tolerated with favorable safety data and supporting PK modeling for dosing every two to three injections over six months.

Absci Corporation (NASDAQ:ABSI) is a medication and target discovery business that uses deep learning AI and synthetic biology to improve the therapeutic potential of proteins. It collaborates with pharmaceutical and biotech developers to develop the next generation of protein-based medicines.